MicroRNA biomarkers for human breast and lung cancer
The present invention relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer.
1. A kit for diagnosing lung cancer comprising a combination of at least two of:
(a) a nucleotide molecule that hybridizes under stringent conditions to SEQ ID NO:20;
(b) a nucleotide molecule that hybridizes under stringent conditions to SEQ ID NO:25; and
(c) a nucleotide molecule that hybridizes under stringent conditions to a nucleotide molecule selected from the group of SEQ ID NO:1, 3, 4, 19, 21, 22, 23, 24, 26, 27, 28, and 29, or a combination thereof,
wherein the nucleotide molecules of (a), (b) and (c) are labeled or immobilized on a solid substrate.
2. A method for detecting, classifying, diagnosing or prognosing and treating lung cancer comprising
(i) obtaining at least one lung sample from an individual;
(ii) detecting the presence or absence of expression and/or the expression level of nucleic acid molecules in cells of the sample, wherein said nucleic acid molecules comprise a combination of at least two of:
(a) SEQ ID NO:20;
(b) SEQ ID NO:25; and
(c) SEQ ID NO:1, 3, 4, 19, 21, 22, 23, 24, 26, 27, 28 or 29, or a combination thereof; and
(iii) treating the subject with
(a) a nucleic acid molecule comprising SEQ ID NO:20,
(b) an agent that hybridizes to SEQ ID NO:25, or
(c) a combination of (a) and (b),
when the expression of SEQ ID NO:20 is absent or downregulated, or the expression of SEQ ID NO:25 is present or upregulated as compared to healthy lung tissue.
3. The method of claim 2 , wherein the nucleic acid molecule comprising SEQ ID NO:20 is a locked nucleic acid-modified molecule.
4. The method of claim 2 , wherein the agent that hybridizes to SEQ ID NO:25 is a locked nucleic acid-modified molecule.